Ticagrelor Versus Cilostazol in Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 900 participants.

Also called NCT06561867

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 900 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06561867
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06561867. Randomized; double masking; primary purpose treatment. Start 2024-08-30 (anticipated); primary completion 2025-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelor Versus Cilostazol in Ischemic Stroke
Intervention (Drug)
Ticagrelor 90 MG
Intervention (Drug)
Cilostazol 100 MG
Lead sponsor
Kafrelsheikh University (class: other)

Record details

Record id
cardio:ct-nct06561867
Content hash
055e13eab9a54709a9d1c499b44509839bee43a09de2a165b5e45cfbe96ff1d0